You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 2
  • A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Article metrics

Article menu

Download PDFPDF

Poster Presentation
A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

 

Online download statistics by month:

Online download statistics by month: December 2019 to November 2024

AbstractFullPdf
Dec 2019020
Jan 2020030
Feb 2020012
Mar 2020025
Apr 2020081
Jun 20200110
Jul 2020050
Aug 2020021
Sep 2020072
Oct 2020090
Nov 2020041
Dec 2020050
Jan 2021033
Feb 2021001
Mar 2021042
Apr 2021050
Jun 2021021
Jul 2021010
Aug 2021020
Sep 2021051
Oct 2021051
Nov 2021097
Dec 2021071
Jan 2022060
Feb 2022021
Mar 2022050
Apr 2022040
May 2022041
Jun 2022072
Jul 20220113
Aug 2022051
Sep 2022072
Oct 2022071
Nov 2022040
Dec 2022061
Jan 2023041
Feb 2023041
Mar 2023020
Apr 2023020
May 2023040
Jun 2023010
Jul 2023022
Aug 2023030
Sep 2023021
Oct 2023061
Nov 2023051
Dec 20230110
Jan 2024040
Feb 20240110
Mar 2024071
Apr 20240101
May 2024091
Jun 2024080
Jul 2024061
Aug 2024062
Sep 2024062
Oct 2024090
Nov 2024050
Total029756